Oligonucleotide (Antisense oligonucleotide) · developed by BioMarin Pharmaceutical
BMN 351 is an antisense oligonucleotide administered intravenously. It is being studied in Duchenne muscular dystrophy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06280209 | Phase 1/2 | Duchenne Muscular Dystrophy | Active not recruiting | BMRN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Duchenne Muscular Dystrophy
Updated Nov 8, 2026. Something wrong or missing? Report it on the BMRN page.
See BMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BMRN catalysts and pipeline →